Short answer
Erasca, Inc. (ERAS) filed an 8-K current report with the SEC on August 24, 2026 reporting Item 8.01 (Other Events). FDA Fast Track Designation granted to ERAS-0015 for metastatic pancreatic adenocarcinoma.
Erasca, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA Fast Track Designation granted to ERAS-0015 for metastatic pancreatic adenocarcinoma
- Potential benefits: more frequent FDA interaction, rolling review, priority review, or accelerated approval eligibility
- FTD does not alter approval standards or guarantee faster review or marketing approval
- Company plans a phase 3 pancreatic cancer trial and two potentially registration-enabling lung cancer trials
- Key risks: inadequate efficacy, adverse effects, FDA-requested delays, or trials failing to support approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Erasca, Inc. 8-K filings
Get the next ERAS 8-K as it lands
Follow ERAS for push alerts, or ask the research agent what this filing means.